The addition of a monthly course of progesterone decreases the incidence of endometrial hyperplasia and endometrial carcinoma. The progesterones used in hormonal replacement therapy (HRT) differ markedly in their progesteronic, androgenic and
even
estrogenic activities, These characteristics may influence both symptomatic and metabolic side effects.
The purpose of this study was to examine effect of bone and lipid metabolism in postmenopausal women treated with conjugated equine estrogens plus dydrogesterone.
A total 131 postmenopausal women(surgical menopause=95, natural menopause=36) and not-treated postmenopausal women(control=22) were invited to participate in this study. Patients were divided into groups which had received conjugated equine
estrogen(CEE) 0.625mg/day 21-day-cycle each month(n=20), CEE 0.625mg/day plus Dydrogesterone 10mg/day 10-day-cycle each month(n=111), and no treatment control group(n=20).
Serum lipid & lipoprotein(Triglyceride, Total cholesterol, High density lipoprotein, Low density lipoprotein) and serum osteocalcin, urinary Deoxypyridinoline were examined in all patients.
There were no significant differences in bone & lipid metabolism between CEE and CEE plus Dydrogesterone groups.
In conclusion, Dydrogesterone may be used safely in postmenopausal women without metabolic side effect.
|